Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam

Clin Pharmacol Ther. 2006 Nov;80(5):549-51. doi: 10.1016/j.clpt.2006.08.003.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Area Under Curve
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Cyclooxygenase 1 / metabolism
  • Cyclooxygenase 2 / metabolism
  • Cyclooxygenase Inhibitors / blood
  • Cyclooxygenase Inhibitors / pharmacokinetics
  • Cytochrome P-450 CYP2C9
  • Genotype
  • Half-Life
  • Humans
  • Metabolic Clearance Rate
  • Piroxicam / blood
  • Piroxicam / pharmacokinetics*
  • Time Factors

Substances

  • Cyclooxygenase Inhibitors
  • Piroxicam
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Cyclooxygenase 1
  • Cyclooxygenase 2